Holen Sie sich die Stockscreener-App
78.11
1.39%
1.115
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NFLX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$77.00
Offen:
$76.61
24-Stunden-Volumen:
15.61M
Relative Volume:
0.34
Marktkapitalisierung:
$329.62B
Einnahmen:
$45.27B
Nettoeinkommen (Verlust:
$10.98B
KGV:
30.91
EPS:
2.5272
Netto-Cashflow:
$9.46B
1W Leistung:
+1.56%
1M Leistung:
-10.53%
6M Leistung:
-35.69%
1J Leistung:
-23.80%
1-Tages-Spanne:
$76.40
$78.23
1-Wochen-Bereich:
$75.30
$78.70
52-Wochen-Spanne:
$75.23
$134.12
Netflix Inc Stock (NFLX) Company Profile
Firmenname
Netflix Inc
Sektor
Branche
Telefon
408-540-3700
Adresse
121 ALBRIGHT WAY, LOS GATOS
Compare NFLX vs DIS, WBD, LYV, FOXA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NFLX
Netflix Inc
|
78.07 | 325.11B | 45.27B | 10.98B | 9.46B | 2.5272 |
|
DIS
Walt Disney Co
|
105.39 | 187.78B | 95.62B | 13.27B | 7.06B | 6.7872 |
|
WBD
Warner Bros Discovery Inc
|
28.71 | 70.74B | 37.87B | 356.00M | 4.13B | 0.1876 |
|
LYV
Live Nation Entertainment Inc
|
164.89 | 36.56B | 24.57B | 532.09M | 1.59B | 1.37 |
|
FOXA
Fox Corporation
|
56.49 | 23.89B | 16.47B | 2.07B | 2.67B | 4.4433 |
Netflix Inc Stock (NFLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-23 | Bestätigt | Robert W. Baird | Outperform |
| 2026-01-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2026-01-21 | Bestätigt | Canaccord Genuity | Buy |
| 2026-01-21 | Bestätigt | Deutsche Bank | Hold |
| 2026-01-21 | Bestätigt | Goldman | Neutral |
| 2026-01-21 | Bestätigt | Guggenheim | Buy |
| 2026-01-21 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2026-01-21 | Bestätigt | Morgan Stanley | Overweight |
| 2026-01-21 | Bestätigt | Needham | Buy |
| 2026-01-21 | Bestätigt | Oppenheimer | Outperform |
| 2026-01-21 | Bestätigt | Piper Sandler | Overweight |
| 2026-01-21 | Bestätigt | Pivotal Research Group | Hold |
| 2026-01-21 | Bestätigt | Rosenblatt | Neutral |
| 2026-01-21 | Bestätigt | Rothschild & Co Redburn | Buy |
| 2026-01-21 | Bestätigt | TD Cowen | Buy |
| 2026-01-21 | Bestätigt | UBS | Buy |
| 2026-01-21 | Bestätigt | Wolfe Research | Outperform |
| 2026-01-12 | Eingeleitet | HSBC Securities | Buy |
| 2026-01-09 | Bestätigt | Goldman | Neutral |
| 2025-12-08 | Herabstufung | Pivotal Research Group | Buy → Hold |
| 2025-12-08 | Herabstufung | Rosenblatt | Buy → Neutral |
| 2025-11-18 | Bestätigt | Barclays | Equal Weight |
| 2025-10-31 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-07 | Hochstufung | Seaport Research Partners | Neutral → Buy |
| 2025-09-17 | Hochstufung | Loop Capital | Hold → Buy |
| 2025-07-10 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2025-07-07 | Herabstufung | Seaport Research Partners | Buy → Neutral |
| 2025-07-02 | Bestätigt | Canaccord Genuity | Buy |
| 2025-07-02 | Bestätigt | Goldman | Neutral |
| 2025-06-20 | Bestätigt | Pivotal Research Group | Buy |
| 2025-06-12 | Bestätigt | Oppenheimer | Outperform |
| 2025-06-03 | Bestätigt | Jefferies | Buy |
| 2025-05-30 | Bestätigt | BofA Securities | Buy |
| 2025-05-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-04-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-04-21 | Bestätigt | Barclays | Equal Weight |
| 2025-04-21 | Bestätigt | Canaccord Genuity | Buy |
| 2025-04-21 | Bestätigt | Guggenheim | Buy |
| 2025-04-21 | Bestätigt | JP Morgan | Overweight |
| 2025-04-21 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2025-04-21 | Bestätigt | MoffettNathanson | Buy |
| 2025-04-21 | Bestätigt | Morgan Stanley | Overweight |
| 2025-04-21 | Bestätigt | Oppenheimer | Outperform |
| 2025-04-21 | Bestätigt | Piper Sandler | Overweight |
| 2025-04-21 | Bestätigt | Pivotal Research Group | Buy |
| 2025-04-21 | Bestätigt | Wells Fargo | Overweight |
| 2025-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-27 | Eingeleitet | FBN Securities | Outperform |
| 2025-03-17 | Hochstufung | MoffettNathanson | Neutral → Buy |
| 2025-01-24 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-01-23 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-01-22 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-01-22 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2025-01-22 | Bestätigt | Oppenheimer | Outperform |
| 2025-01-22 | Bestätigt | Pivotal Research Group | Buy |
| 2025-01-22 | Hochstufung | Rosenblatt | Neutral → Buy |
| 2025-01-22 | Hochstufung | The Benchmark Company | Sell → Hold |
| 2025-01-16 | Hochstufung | Seaport Research Partners | Neutral → Buy |
| 2025-01-15 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-01-15 | Bestätigt | Oppenheimer | Outperform |
| 2025-01-08 | Bestätigt | Goldman | Neutral |
| 2025-01-06 | Bestätigt | Argus | Buy |
| 2025-01-03 | Bestätigt | The Benchmark Company | Sell |
| 2024-12-19 | Bestätigt | UBS | Buy |
| 2024-12-16 | Herabstufung | Loop Capital | Buy → Hold |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-11 | Bestätigt | JP Morgan | Overweight |
| 2024-11-20 | Bestätigt | Pivotal Research Group | Buy |
| 2024-10-18 | Bestätigt | Needham | Buy |
| 2024-10-18 | Bestätigt | Oppenheimer | Outperform |
| 2024-10-18 | Bestätigt | Pivotal Research Group | Buy |
| 2024-10-16 | Bestätigt | Loop Capital | Buy |
| 2024-10-11 | Bestätigt | Guggenheim | Buy |
| 2024-10-10 | Bestätigt | Morgan Stanley | Overweight |
| 2024-10-10 | Bestätigt | Oppenheimer | Outperform |
| 2024-10-07 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-10-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-10-01 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2024-09-05 | Eingeleitet | China Renaissance | Hold |
| 2024-08-30 | Bestätigt | Pivotal Research Group | Buy |
| 2024-07-17 | Bestätigt | Guggenheim | Buy |
| 2024-07-16 | Bestätigt | The Benchmark Company | Sell |
| 2024-07-15 | Bestätigt | BofA Securities | Buy |
| 2024-07-12 | Bestätigt | JP Morgan | Overweight |
| 2024-07-10 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2024-07-09 | Bestätigt | TD Cowen | Buy |
| 2024-07-02 | Bestätigt | Argus | Buy |
| 2024-05-28 | Bestätigt | Evercore ISI | Outperform |
| 2024-04-19 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-04-19 | Hochstufung | Needham | Hold → Buy |
| 2024-04-19 | Bestätigt | Pivotal Research Group | Buy |
| 2024-04-15 | Bestätigt | Deutsche Bank | Hold |
| 2024-04-12 | Bestätigt | Morgan Stanley | Overweight |
| 2024-04-12 | Bestätigt | Piper Sandler | Neutral |
| 2024-04-05 | Bestätigt | Pivotal Research Group | Buy |
| 2024-03-25 | Bestätigt | Citigroup | Neutral |
| 2024-03-12 | Bestätigt | Jefferies | Buy |
| 2024-03-11 | Bestätigt | Oppenheimer | Outperform |
| 2024-01-30 | Herabstufung | Seaport Research Partners | Buy → Neutral |
| 2024-01-25 | Hochstufung | DZ Bank | Hold → Buy |
| 2024-01-24 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-01-24 | Bestätigt | BofA Securities | Buy |
| 2024-01-24 | Bestätigt | Canaccord Genuity | Buy |
| 2024-01-24 | Bestätigt | Evercore ISI | Outperform |
| 2024-01-24 | Bestätigt | Goldman | Neutral |
| 2024-01-24 | Bestätigt | Guggenheim | Buy |
| 2024-01-24 | Bestätigt | JP Morgan | Overweight |
| 2024-01-24 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2024-01-24 | Hochstufung | Macquarie | Neutral → Outperform |
| 2024-01-24 | Bestätigt | Morgan Stanley | Overweight |
| 2024-01-24 | Bestätigt | Oppenheimer | Outperform |
| 2024-01-24 | Bestätigt | Piper Sandler | Neutral |
| 2024-01-24 | Bestätigt | Pivotal Research Group | Buy |
| 2024-01-24 | Bestätigt | Redburn Atlantic | Buy |
| 2024-01-24 | Bestätigt | Robert W. Baird | Outperform |
| 2024-01-24 | Bestätigt | TD Cowen | Outperform |
| 2024-01-24 | Bestätigt | UBS | Buy |
| 2024-01-24 | Bestätigt | Wells Fargo | Overweight |
| 2023-09-18 | Bestätigt | Evercore ISI | Outperform |
| 2023-08-25 | Hochstufung | Loop Capital | Hold → Buy |
| 2023-07-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-07-17 | Bestätigt | Deutsche Bank | Buy |
| 2023-07-13 | Bestätigt | JP Morgan | Overweight |
| 2023-07-12 | Bestätigt | UBS | Buy |
| 2023-07-05 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-29 | Bestätigt | Citigroup | Buy |
| 2023-06-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-06-13 | Bestätigt | BofA Securities | Buy |
| 2023-06-13 | Bestätigt | Guggenheim | Buy |
| 2023-04-19 | Bestätigt | Deutsche Bank | Buy |
| 2023-04-19 | Bestätigt | JP Morgan | Overweight |
| 2023-04-19 | Bestätigt | Jefferies | Buy |
| 2023-04-19 | Bestätigt | Piper Sandler | Neutral |
| 2023-04-19 | Bestätigt | Pivotal Research Group | Buy |
| 2023-04-19 | Bestätigt | Rosenblatt | Neutral |
| 2023-04-19 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-11 | Fortgesetzt | Robert W. Baird | Neutral |
| 2023-01-23 | Bestätigt | Argus | Buy |
| 2023-01-20 | Bestätigt | Canaccord Genuity | Buy |
| 2023-01-20 | Bestätigt | Deutsche Bank | Buy |
| 2023-01-20 | Bestätigt | Evercore ISI | Outperform |
| 2023-01-20 | Bestätigt | Goldman | Sell |
| 2023-01-20 | Bestätigt | Guggenheim | Buy |
| 2023-01-20 | Bestätigt | Jefferies | Buy |
| 2023-01-20 | Bestätigt | MoffettNathanson | Market Perform |
| 2023-01-20 | Bestätigt | Oppenheimer | Outperform |
| 2023-01-20 | Bestätigt | Piper Sandler | Neutral |
| 2023-01-20 | Bestätigt | Pivotal Research Group | Buy |
| 2023-01-20 | Bestätigt | Robert W. Baird | Neutral |
| 2023-01-20 | Bestätigt | The Benchmark Company | Sell |
| 2023-01-20 | Bestätigt | Wedbush | Outperform |
| 2023-01-20 | Bestätigt | Wolfe Research | Outperform |
| 2023-01-12 | Hochstufung | Jefferies | Hold → Buy |
| 2023-01-04 | Eingeleitet | New Street | Neutral |
| 2022-12-29 | Hochstufung | CFRA | Sell → Buy |
| 2022-12-14 | Bestätigt | Jefferies | Hold |
| 2022-12-09 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-06-14 | Herabstufung | The Benchmark Company | Hold → Sell |
| 2022-06-10 | Herabstufung | Goldman | Neutral → Sell |
| 2022-05-16 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-04-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-04-21 | Herabstufung | Edward Jones | Buy → Hold |
| 2022-04-20 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-04-20 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-04-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-04-20 | Hochstufung | Needham | Underperform → Hold |
| 2022-04-20 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-04-20 | Herabstufung | Pivotal Research Group | Buy → Sell |
| 2022-04-20 | Herabstufung | Stifel | Buy → Hold |
| 2022-04-20 | Herabstufung | UBS | Buy → Neutral |
| 2022-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-19 | Eingeleitet | Rosenblatt | Neutral |
| 2022-03-09 | Hochstufung | Wedbush | Underperform → Neutral |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Edward Jones | Hold → Buy |
| 2022-01-24 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-01-21 | Bestätigt | BofA Securities | Buy |
| 2022-01-21 | Bestätigt | Canaccord Genuity | Buy |
| 2022-01-21 | Bestätigt | Cowen | Outperform |
| 2022-01-21 | Bestätigt | Deutsche Bank | Hold |
| 2022-01-21 | Bestätigt | Goldman | Neutral |
| 2022-01-21 | Bestätigt | Guggenheim | Buy |
| 2022-01-21 | Bestätigt | JP Morgan | Overweight |
| 2022-01-21 | Bestätigt | MoffettNathanson | Neutral |
| 2022-01-21 | Herabstufung | Monness Crespi & Hardt | Buy → Neutral |
| 2022-01-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-21 | Bestätigt | Oppenheimer | Outperform |
| 2022-01-21 | Bestätigt | Piper Sandler | Overweight |
| 2022-01-21 | Bestätigt | Pivotal Research Group | Buy |
| 2022-01-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-01-21 | Bestätigt | Stifel | Buy |
| 2022-01-21 | Hochstufung | The Benchmark Company | Sell → Hold |
| 2022-01-21 | Herabstufung | Truist | Buy → Hold |
| 2022-01-21 | Bestätigt | UBS | Buy |
| 2022-01-21 | Bestätigt | Wolfe Research | Outperform |
| 2021-12-15 | Bestätigt | The Benchmark Company | Sell |
| 2021-10-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-10-20 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2021-09-29 | Bestätigt | The Benchmark Company | Sell |
| 2021-09-13 | Eingeleitet | Goldman | Neutral |
| 2021-09-08 | Bestätigt | JP Morgan | Overweight |
| 2021-09-07 | Bestätigt | Atlantic Equities | Overweight |
| 2021-07-21 | Bestätigt | Credit Suisse | Outperform |
| 2021-07-21 | Bestätigt | Deutsche Bank | Buy |
| 2021-07-21 | Bestätigt | JP Morgan | Overweight |
| 2021-07-21 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2021-07-21 | Bestätigt | Stifel | Buy |
| 2021-06-25 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-06-25 | Eingeleitet | Edward Jones | Hold |
| 2021-05-19 | Fortgesetzt | Jefferies | Buy |
| 2021-04-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2021-04-21 | Bestätigt | Pivotal Research Group | Buy |
| 2021-04-21 | Hochstufung | Stifel | Hold → Buy |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-04-01 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-25 | Bestätigt | The Benchmark Company | Sell |
| 2021-03-23 | Hochstufung | Argus | Hold → Buy |
| 2021-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-01-20 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2021-01-20 | Bestätigt | Pivotal Research Group | Buy |
| 2021-01-20 | Bestätigt | The Benchmark Company | Sell |
| 2021-01-20 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2020-10-21 | Bestätigt | Bernstein | Outperform |
| 2020-10-21 | Bestätigt | Jefferies | Buy |
| 2020-10-21 | Bestätigt | Morgan Stanley | Overweight |
| 2020-10-21 | Bestätigt | Oppenheimer | Outperform |
| 2020-10-21 | Bestätigt | Piper Sandler | Overweight |
| 2020-10-21 | Bestätigt | Pivotal Research Group | Buy |
| 2020-10-21 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-10-21 | Bestätigt | The Benchmark Company | Sell |
| 2020-10-21 | Bestätigt | Wedbush | Underperform |
| 2020-10-21 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-10-16 | Bestätigt | Morgan Stanley | Overweight |
| 2020-10-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-10-14 | Bestätigt | Goldman | Buy |
| 2020-10-07 | Bestätigt | Pivotal Research Group | Buy |
| 2020-09-28 | Bestätigt | The Benchmark Company | Sell |
| 2020-09-15 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-09-09 | Fortgesetzt | Raymond James | Mkt Perform |
| 2020-09-04 | Bestätigt | The Benchmark Company | Sell |
| 2020-07-29 | Bestätigt | Loop Capital | Buy |
Alle ansehen
Netflix Inc Aktie (NFLX) Neueste Nachrichten
Paramount Clears A U.S. Antitrust Hurdle In Bid For Warner Bros. Discovery; Netflix Notes Rival Is “A Long Way” From Getting Regulatory Signoffs — Update - IMDb
Antony Starr's Netflix Thriller Series 'Breakers' Rounds Out Cast - IMDb
Netflix doesn't need the Warner Bros. deal, but its rivals might - Yahoo! Finance Canada
Meta Platforms vs. Netflix: Which Is the Better Growth Stock to Buy? - The Motley Fool
Netflix drama, Christmas feature among multiple productions filming in region - DiscoverAirdrie
'Anemone': Netflix Release Date Revealed for Daniel Day-Lewis' Comeback - IMDb
Mckenna Grace to play Daphne in 'Scooby-Doo' live-action series at Netflix. Read more below. - facebook.com
Netflix (NFLX) Analyst Rating Reiterated at Outperform by Wedbus - GuruFocus
James Cameron Raises Concerns Over Netflix's Warner Bros. Acquisition - Intellectia AI
James Cameron just made 3 arguments against Netflix buying Warner Bros. The last one has stakes for the entire world - Fast Company
Media Deals Value Surges to $250 Billion Last Year, Driven by Netflix-Warner Bros., Premium Content - Yahoo Finance
Jupiter Asset Management Ltd. Has $128.30 Million Holdings in Netflix, Inc. $NFLX - MarketBeat
'China's Netflix' Looks For Stardom In New Theme Park Business - Benzinga
Netflix (NFLX) Stock: Why a Billionaire Just Bought 10 Million Shares at a 42% Discount - Blockonomi
A dash of ‘schmuck insurance’ could help Netflix win Warner Bros - Financial Times
‘Severance’ Producer Boards Sequel to Nigerian Netflix Hit ‘Black Book’ (Exclusive) - IMDb
James Cameron voices concerns over 'disastrous' Netflix-Warner Bros. deal in letter - Yahoo Finance
Noah Kahan headed to Netflix with documentary about rise from VT roots - Burlington Free Press
Why this $2.7-billion money manager is buying Netflix and selling Adobe - The Globe and Mail
Netflix (NFLX) Stock; Drops Marginally While Considering Higher Warner Bros. Bid - CoinCentral
Netflix Poised to Shore Up Bid in Heated Warner Bros Acquisition Race - StockInvest.us
James Cameron wrote a letter Sen. Mike Lee, chairman of the Senate antitrust subcommittee, saying a Netflix-Warner Bros deal would threaten movie theaters. Read more below. - facebook.com
James Cameron Sounds Alarm Over Netflix-Warner Bros. Deal, Backs Paramount - IMDb
Apple Just Took a Page Straight Out of the Netflix Playbook. Here's Why It Could Be a Brilliant Move - Yahoo Finance
‘A Friend, A Murderer’ Launches on Netflix on March 5, 2026 - About Netflix
Netflix has ample room to increase its offer in battle for Warner Bros, sources say - The Spokesman-Review
Netflix co-CEO says Warner deal to put more films in cinemas - The Business Times
‘Avatar’ Director James Cameron Calls Netflix-WBD Disastrous, Bats For Paramount Takeover - Stocktwits
Netflix stock slips to $77 as Warner bid battle nears Monday deadline - Bez Kabli
James Cameron Warns of ‘Disastrous’ Potential of Netflix-WBD Deal in Fiery Letter to Lawmaker - Yahoo News Canada
Inside Warner Bros. Discovery, Mood Among Many Staffers Shifts in Favor of Netflix Sale vs. Paramount Takeover - IMDb
Netflix (NASDAQ: NFLX) defends $27.75 WBD asset bid amid Paramount rival - Stock Titan
Netflix to stage WBC public viewings at 150 locations in Japan - Japan Today
Ted Sarandos Promises Netflix Will Include Premium On-Demand in Warner Theatrical Window - IMDb
Netflix stock dips as Warner bid fight heats up and DOJ questions hang over the deal - Bez Kabli
Netflix Says Warner Bros. Acquisition Would Put ‘More’ Movies In Theaters - Forbes
Ted Sarandos Blames Netflix Stock Decline on Wbd Bidding War, Industry Uncertainty and AI - IMDb
Netflix Consumers File Lawsuit Seeking to Block $82.7B Warner Bros. Merger - Law.com
Gordon Ramsay on His Netflix Doc Series and Never Cooking for His Abusive, Alcoholic Father: ‘Maybe That’s a Good Thing’ - IMDb
Ted Sarandos Blames Netflix Stock Decline on WBD Bidding War, Industry Uncertainty and AI - TheWrap
Netflix Stock Dips Amid Warner Bros. Discovery Acquisition News - techi.com
Netflix Could Hike Offer For WBD If Rival Bidder Paramount Does: Report - Stocktwits
Netflix Stock Slides As The Battle For Warner Bros Continues - Benzinga
Netflix May Increase Bid for Warner Bros. Discovery Amid Rivalry - Intellectia AI
Netflix Co-CEO Says Warner Deal to Put More Films in Cinemas - Bloomberg
Is Netflix stock a buy, sell, or hold in 2026? - MSN
Netflix Has Ample Room to Increase Its Offer in Battle for Warner Bros, Sources Say - GV Wire
Sports On Streamers Up 52% In Q1, Prime Video Leads 02/19/2026 - MediaPost
Is Netflix Stock a Buy, Sell, or Hold in 2026? - AOL.com
Exclusive-Netflix has ample room to increase its offer in battle for Warner Bros, sources say By Reuters - Investing.com
Netflix's co-CEO says Trump has one big question about the Warner Bros. sale - Business Insider
Finanzdaten der Netflix Inc-Aktie (NFLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
0.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):